OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MBED57

Arab Pesticides and Veterinary Drugs Manufacturing Company PSC

Agricultural ChemicalsVerified

Mobedco-Vet maintains a strong liquidity position, with a current ratio of 5.56, indicating that it holds significantly more current assets than current liabilities. The company's cash and equivalents amount to JOD 6,937,590, while its long-term debt is JOD 7,609,880, resulting in a net cash position that is negative after subtracting total debt. This suggests that the company may need to manage its debt obligations carefully in the near term. In terms of profitability, Mobedco-Vet demonstrates a return on equity (ROE) of 14.84% and a return on assets (ROA) of 9.86%, both of which are strong indicators of efficient capital utilization and asset management. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key performance indicators. The company's operating income of JOD 8,191,390 and net income of JOD 6,038,510 further support its profitability. Mobedco-Vet's revenue is distributed across two primary segments: Veterinary Drug products and Agrochemical products. The company exports its products to over 30 countries in Eastern Europe, North and Central Africa, indicating a diversified geographic exposure. However, the exact revenue concentration by segment or region is not disclosed, which limits the ability to assess potential concentration risks. The company's growth trajectory is supported by its operating cash flow of JOD 3,025,360 and free cash flow of JOD 4,505,810, which provide flexibility for reinvestment or debt reduction. The outlook for the current fiscal year (FY) and the next FY is not explicitly provided, but the company's capital expenditure of JOD -1,709,350 suggests a focus on maintaining or optimizing existing operations rather than aggressive expansion. Risk factors for Mobedco-Vet include medium liquidity risk, as indicated by the risk assessment, and the potential for dilution, although it is currently rated as low. The company's debt-to-equity ratio of 0.19 suggests a relatively conservative capital structure, but the negative net cash position after subtracting total debt indicates a need for careful liquidity management. No specific dilution sources are disclosed, and the dilution potential is not expected to be significant in the near term. Recent events and filings for Mobedco-Vet are not detailed in the provided data, so no specific recent developments can be cited. The company's financial and operational performance appears to be stable, but ongoing monitoring of its liquidity and debt management strategies is recommended.

30-day price · MBED+0.21 (+5.5%)
Low$3.65High$4.39Close$4.00As of12 May, 00:00 UTC
Profile
CompanyArab Pesticides and Veterinary Drugs Manufacturing Company PSC
TickerMBED.AM
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryAgricultural Chemicals
AI analysis

Business. Arab Pesticides and Veterinary Drugs Manufacturing Company PSC (Mobedco-Vet) is a Jordan-based public shareholding company that produces agricultural pesticides, public health pesticides, and veterinary medicine, with products structured into two main divisions: Veterinary Drug products and Agrochemical products.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Agricultural Chemicals industry, with a classification confidence of 0.92.

Mobedco-Vet maintains a strong liquidity position, with a current ratio of 5.56, indicating that it holds significantly more current assets than current liabilities. The company's cash and equivalents amount to JOD 6,937,590, while its long-term debt is JOD 7,609,880, resulting in a net cash position that is negative after subtracting total debt. This suggests that the company may need to manage its debt obligations carefully in the near term. In terms of profitability, Mobedco-Vet demonstrates a return on equity (ROE) of 14.84% and a return on assets (ROA) of 9.86%, both of which are strong indicators of efficient capital utilization and asset management. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key performance indicators. The company's operating income of JOD 8,191,390 and net income of JOD 6,038,510 further support its profitability. Mobedco-Vet's revenue is distributed across two primary segments: Veterinary Drug products and Agrochemical products. The company exports its products to over 30 countries in Eastern Europe, North and Central Africa, indicating a diversified geographic exposure. However, the exact revenue concentration by segment or region is not disclosed, which limits the ability to assess potential concentration risks. The company's growth trajectory is supported by its operating cash flow of JOD 3,025,360 and free cash flow of JOD 4,505,810, which provide flexibility for reinvestment or debt reduction. The outlook for the current fiscal year (FY) and the next FY is not explicitly provided, but the company's capital expenditure of JOD -1,709,350 suggests a focus on maintaining or optimizing existing operations rather than aggressive expansion. Risk factors for Mobedco-Vet include medium liquidity risk, as indicated by the risk assessment, and the potential for dilution, although it is currently rated as low. The company's debt-to-equity ratio of 0.19 suggests a relatively conservative capital structure, but the negative net cash position after subtracting total debt indicates a need for careful liquidity management. No specific dilution sources are disclosed, and the dilution potential is not expected to be significant in the near term. Recent events and filings for Mobedco-Vet are not detailed in the provided data, so no specific recent developments can be cited. The company's financial and operational performance appears to be stable, but ongoing monitoring of its liquidity and debt management strategies is recommended.
Key takeaways
  • Mobedco-Vet maintains a strong liquidity position with a current ratio of 5.56.
  • The company's ROE of 14.84% and ROA of 9.86% indicate efficient capital and asset utilization.
  • The company's revenue is distributed across two primary segments and exported to over 30 countries.
  • The company's capital expenditure suggests a focus on maintaining or optimizing existing operations.
  • The company faces medium liquidity risk and a low dilution potential.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJOD
Revenue$35.9M
Gross profit$12.4M
Operating income$8.2M
Net income$6.0M
R&D
SG&A
D&A
SBC
Operating cash flow$3.0M
CapEx-$1.7M
Free cash flow$4.5M
Total assets$61.3M
Total liabilities$20.6M
Total equity$40.7M
Cash & equivalents$6.9M
Long-term debt$7.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$40.7M
Net cash-$672.3k
Current ratio5.6
Debt/Equity0.2
ROA9.9%
ROE14.8%
Cash conversion50.0%
CapEx/Revenue-4.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
MetricMBEDActivity
Op margin22.8%0.4% medp25 -8.0% · p75 16.0%top quartile
Net margin16.8%2.3% medp25 -11.6% · p75 11.8%top quartile
Gross margin34.5%20.8% medp25 14.9% · p75 24.0%top quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-4.8%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity19.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 09:32 UTC#2b3387c2
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 09:35 UTCJob: cea0f478